Rubraca®
(rucaparib) 300 mg tablets

YOUR SHIELD AGAINST PROGRESSION IN ADVANCED PROSTATE CANCER

Fight for what matters with RUBRACA

With RUBRACA by your side, you can defend against *BRCA*-mutated advanced prostate cancer[1]*

*RUBRACA treats metastatic castration-resistant prostate cancer, or mCRPC, which is prostate cancer that has spread to other parts of the body (metastatic) and that no longer responds to testosterone-lowering medical or surgical treatment.

SELECT IMPORTANT SAFETY INFORMATION

What is RUBRACA used for?

RUBRACA tablets are a prescription medicine used in adults for:

- The treatment of castration-resistant prostate cancer (prostate cancer that no longer responds to medical or surgical treatment that lowers testosterone):
  - That has spread to other parts of the body (metastatic), and
  - Has a certain type of inherited (germline) or acquired (somatic) abnormal *BRCA* gene, and you have been treated with certain medicines for your cancer.

Your healthcare provider will perform a test to make sure RUBRACA is right for you.

It is not known if RUBRACA is safe and effective in children.

Please see additional Important Safety Information throughout and full Prescribing Information.

RUBRACA IS HERE FOR THE NEXT STEP OF YOUR TREATMENT JOURNEY

Navigating advanced prostate cancer management can be challenging, making treatment decisions difficult. Use this guide to understand why RUBRACA might be the right treatment for you.

RUBRACA is a type of drug called a poly (adenosine diphosphate-ribose) polymerase inhibitor, otherwise known as a PARP inhibitor. RUBRACA is used in patients who meet the following requirements[1]:

- Cancer has spread to other parts of the body (metastasized)
- Cancer is no longer responding to medical or surgical treatment that lowers testosterone (castration resistant)
- Based on genetic testing, you are positive for one of the *BRCA*, or BReast CAncer, gene mutations (*BRCA1* or *BRCA2*)
  - Having a *BRCA* gene mutation means that you have inherited or acquired a gene that can put you at higher risk for certain cancers, including prostate cancer[2,3]

RUBRACA IS THE ONLY PARPi THAT CAN BE USED ALONE FOLLOWING ANY ANDROGEN RECEPTOR-DIRECTED THERAPY AND A TAXANE-BASED CHEMOTHERAPY[1,4-6]*

*Patients should also receive a gonadotropin-releasing hormone (GnRH) analog concurrently or should have had bilateral orchiectomy.

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What Warnings should you know about RUBRACA?

RUBRACA tablets may cause serious side effects including: bone marrow problems called Myelodysplastic Syndrome (MDS) or a type of cancer of the blood called Acute Myeloid Leukemia (AML). Some people who have cancer and who have received previous treatment with chemotherapy or certain other medicines for their cancer have developed MDS or AML during or after treatment with RUBRACA.

MDS or AML may lead to death. If you develop MDS or AML, your healthcare provider will stop treatment with RUBRACA. Symptoms may include weakness, weight loss, fever, frequent infections, blood in urine or stool, shortness of breath, feeling very tired, bruising or bleeding more easily. Symptoms of low blood cell counts are common during treatment with RUBRACA, but can be a sign of serious problems, including MDS or AML.

Please see additional Important Safety Information throughout and full Prescribing Information.

Rubraca® (rucaparib) 300 mg tablets

HOW RUBRACA WORKS[1,7,8]

PARP and BRCA are proteins in the body that help repair damaged DNA in cells. While this repair is what healthy cells need to survive, when PARP and BRCA repair DNA in cancer cells, it helps them grow and spread. If you have the *BRCA* mutation, your *BRCA*-mutated cancer cells depend on PARP for DNA repair.



A PARP inhibitor like RUBRACA can stop the PARP protein from repairing DNA in cells, including cancer cells.

When damaged DNA cannot be repaired, the cell dies, helping reduce the growth and spread of cancer cells.

Source: Zheng et al. *Biomed Pharmacother*. 2020;123:109661.

RUBRACA HAS BEEN PROVEN EFFECTIVE FOR ADVANCED PROSTATE CANCER

Results are from 81 patients who had *BRCA*-mutated advanced prostate cancer and were treated with RUBRACA after previous treatment with any androgen receptor-directed therapy and a taxane-based chemotherapy.[1,9]

- **46%** of patients achieved a reduction in disease, called an objective response rate[9]
- **15.5 months** was the median length of time the cancer responded to treatment, also known as the median duration of response[9]
- **67%** of patients saw at least a 30% decrease in tumor size[9]

This indication is approved under accelerated approval based on objective response rate and duration of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials.

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

Before you take RUBRACA, tell your healthcare provider about all of your medical conditions, including if you are a male with a female partner who is pregnant or able to become pregnant, effective birth control should be used during treatment and for 3 months after the last dose of RUBRACA. Do not donate sperm during use and for 3 months after the last dose of RUBRACA.

Please see additional Important Safety Information throughout and full Prescribing Information.

Rubraca® (rucaparib) 300 mg tablets

RUBRACA IS TAKEN TWICE DAILY[1]

RUBRACA's dosing schedule makes it easy to fit treatment into your daily lifestyle

- 2 tablets taken twice a day, 12 hours apart
- Ability to be taken with or without food
- If you miss a dose or vomit, take your next dose at your usual scheduled time. Do not take an extra dose to make up for a missed dose
- You may be directed to take RUBRACA along with other medications that treat prostate cancer
- Always take RUBRACA as directed by your doctor. Do not stop treatment without speaking with your healthcare team first

Be sure to let your doctor know of any other medications you may be taking, as RUBRACA could interact with other drugs.

RUBRACA may cause side effects

The most common side effects reported with RUBRACA include tiredness/weakness, nausea, decrease in hemoglobin (anemia), changes in liver function tests, decreased appetite, rash, constipation, low blood cell counts, vomiting, and diarrhea.

Your doctor will monitor you to assess how you are responding to treatment, and may make changes to your treatment to help manage your side effects.

ALERT YOUR DOCTOR ABOUT ANY MISSED DOSES OR SIDE EFFECTS YOU EXPERIENCE, AS DOSE CHANGES OR ADJUSTMENTS MAY BE NEEDED

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What other important information should I know about RUBRACA?

Your healthcare provider will do blood tests before and every month during treatment with RUBRACA to monitor your blood cell counts. Weekly blood tests will be performed if you have low blood cell counts for a long time. Your healthcare provider may stop treatment with RUBRACA until your blood cell counts improve.

Avoid spending time in sunlight while on RUBRACA since your skin may become more sensitive to the sun and may sunburn more easily. You should wear a hat and clothes that cover your skin and use sunscreen to help protect against sunburn if you have to be in the sunlight.

Please see additional Important Safety Information throughout and full Prescribing Information.

Rubraca® (rucaparib) 300 mg tablets

KEY QUESTIONS TO ASK YOUR DOCTOR

Make sure to ask your doctor questions during treatment with RUBRACA, including:

- What should I expect with RUBRACA?
- What are the potential side effects of RUBRACA, and are there things that can help me manage side effects?
- How often do I have to take RUBRACA?
- Are there activities or tips that can help me stay healthy and cope while receiving prostate cancer treatment?

BE PREPARED FOR YOUR APPOINTMENT WITH THE DOCTOR DISCUSSION GUIDE– VISIT RubracaProstate.com

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What are the side effects of RUBRACA?

The most common side effects of RUBRACA in people with prostate cancer include:

Tiredness or weakness, nausea, decrease in hemoglobin (anemia), changes in liver and function tests, decreased appetite, rash, constipation, low blood cell counts, vomiting, and diarrhea. These are not all the possible side effects of RUBRACA. Call your healthcare provider for medical advice about side effects.

Please see additional Important Safety Information throughout and full Prescribing Information.

Rubraca® (rucaparib) 300 mg tablets

ASSISTANCE PROGRAMS ARE HERE TO HELP

QUICKSTART PROGRAM*

- Helps you start RUBRACA if you experience coverage delays regardless of income or insurance. If eligible, you may receive RUBRACA in 15-day increments for up to 60 days (2 months) while coverage is pending or until alternate funding resources have been identified and approved

COVERAGE LINK PROGRAM*

- Provides RUBRACA in 15-day increments (up to 90 days) if you are eligible and experiencing a change in commercial insurance status. This includes switching to a new insurer following a job change or switching plans during an employer's annual enrollment period

RUBRACA CO-PAY ASSISTANCE PROGRAM*†

- Pay as little as $0 if you're an eligible patient with private or commercial insurance who has been prescribed RUBRACA

PATIENT ASSISTANCE PROGRAM (PAP)*

- Available if you are eligible and are uninsured or cannot afford medication

*Terms & Conditions may apply.

†TERMS & CONDITIONS FOR THE pharma& CO-PAY PROGRAM

- This offer is only available to patients with commercial insurance. The program is not available for patients who receive reimbursement under any federal, state or government-funded insurance programs, including patients who: (i) are enrolled in Medicare, Medicare Advantage, Medigap, Medicaid, TRICARE, VA, DoD, or any other federal or state health care program; (ii) are not using insurance coverage at all; (iii) are enrolled in an insurance plan that reimburses for the entire cost of the drug; or (iv) where product is not covered by patient's insurance
- The value of this program is exclusively for the benefit of patients and is intended to be credited toward patient out-of-pocket obligations, including applicable co-payments, coinsurance, and deductibles. You agree that you are personally responsible for paying any amount of co-pay required after the savings card is applied
- May not be available if your insurance company or health plan implements either an accumulator adjustment or co-pay maximizer program. Patient is responsible for complying with any applicable limitations and requirements of his/her health plan related to the use of the program. The program may not be used if prohibited by a patient's health insurer
- Patient may not seek reimbursement for the value received from this program from other parties, including any health insurance program or plan, flexible spending account, or health care savings account. This program may not be combined with any other financial assistance program, free trial, discount, rebate, coupon, or other offer
- Program is not valid where prohibited by law. Valid only in the United States and Puerto Rico. This program is not health insurance
- pharma& reserves the right to make eligibility determinations and to rescind, revoke, or amend the program and discontinue support at any time without notice
- For complete information about the Terms & Conditions of this program, including the limitations on use and the amount of assistance, go to www.RubracaProstate.com or call 1-844-779-7707

These Terms & Conditions are effective as of 01/01/2025.

Please see full Terms & Conditions for the Co-Pay Program and all other access programs at www.RubracaProstate.com/resources-and-support/assistance-programs.

Please see Important Safety Information throughout and full Prescribing Information.

Rubraca® (rucaparib) 300 mg tablets

INCREMENTAL

IncreMENtal is the only habit-building program to support you and your care partner as you build a healthier lifestyle on your prostate cancer journey. Fully online courses have:

Easy-to-follow food, fitness, and mental health tips

Personal progress tracking to help set and keep goals

Comprehensive information in a simple, digestible format

New weekly information to help change habits step by step

Learn more at IncreMENtalADT.com

SUPPORT FOR YOU & YOUR CARE PARTNERS

Whether a patient or a care partner, it is important to know what to expect during RUBRACA treatment.

DISCOVER HELPFUL TIPS AND RESOURCES FOR CARE PARTNERS AT RubracaProstate.com

Please see Important Safety Information throughout and full Prescribing Information.

Rubraca® (rucaparib) 300 mg tablets

RUBRACA IS HERE TO SUPPORT YOU AS YOU FACE ADVANCED PROSTATE CANCER.
LEARN MORE AT RubracaProstate.com

Rubraca®
(rucaparib) 300 mg tablets

SELECT IMPORTANT SAFETY INFORMATION (CONTINUED)

What other medications might interact with RUBRACA?

RUBRACA can increase the amounts of other medications you may be taking, which can increase the risk of side effects. Tell your healthcare provider about all your medical conditions and all medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to pharma& at 1-800-506-8501.

This information is not comprehensive. How to get more information:

- *Talk to your healthcare provider or pharmacist.*
- *Visit RubracaProstate.com to obtain the FDA-approved product labeling.*

Please see full Prescribing Information.

References: 1. RUBRACA (rucaparib). Prescribing Information. pharma& Schweiz GmbH. 2023. **2.** BRCA gene changes: cancer risk and genetic testing. National Cancer Institute. https://www.cancer.gov/about-cancer/causes-prevention/genetics/brca-fact-sheet **3.** Referenced with permission from the NCCN Guidelines for Patients® for Prostate Cancer: Advanced Stage. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed November 1, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. **4.** Lynparza (olaparib). Prescribing Information. AstraZeneca Pharmaceuticals LP. 2023. **5.** Akeega (niraparib and abirateone acetate). Prescribing Information. Janssen Biotech, Inc. 2023. **6.** Talzenna (talazoparib). Prescribing Information. Pfizer Inc. 2024. **7.** Messina C, Cattrini Ci, Soldato D, et al. *BRCA* mutations in prostate cancer: prognostic and predictive implications. *J Oncol*. 2020;4986365. **8.** Zheng F, Zhang Y, Chen S, Weng X, Rao Y, Fang H. Mechanism and current progress of poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer. *Biomed Pharmacother*. 2020;123:109661. **9.** Abida W, Campbell D, Patnaik A, et al. Rucaparib for the treatment of metastatic castration-resistant prostate cancer associated with a DNA damage repair gene alteration: final results from the phase 2 TRITON2 study. *Eur Urol*. 2023;84:321-330.

The individuals pictured in this piece are models, and the images are being used for illustrative purposes only.

tolmar